Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: JONAHLOMU

Well for obvious reasons I hope you are incorrect and the reason that the PTO rejected the two patents was because someone familiar with the patents was not present during any meetings,phone conversations or any other form of communication with the examiners. The flawed description the examiner provided of the handshaking protocol indicated to me that the examiner did not have a clear grasp of the design. We shall see.

Regarding how high the stakes are, I couldn't agree with you more. But with a high profile court case going on with the T2 and numerous ongoing licensing negotiations being conducted, it seems incredibly naive that public knowledge of this dispute wouldn't adversely affect either of the above. Yet with that knowledge all the dirty laundry was laid out in the open which contradicts your theory. It also seems coincidental that this dispute was resolved only after PTSC investors became aware of it, contacted PTSC, and PTSC applied pressure to CM and more than likely TPL.

I have high regard for CM and I don't blame him. Hopefully investors have not been adversely affected in the meantime. But if I am correct then investors should be aware that certain parties could make use of investor emotions to affect certain outcomes. Nothing new of course.

Share
New Message
Please login to post a reply